Report cover image

Lung Disease Therapeutics

Published Jul 01, 2025
Length 389 Pages
SKU # GJOB20171781

Description

Global Lung Disease Therapeutics Market to Reach US$106.0 Billion by 2030

The global market for Lung Disease Therapeutics estimated at US$80.6 Billion in the year 2024, is expected to reach US$106.0 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Asthma Disease, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$65.0 Billion by the end of the analysis period. Growth in the Lung Cancer Disease segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$22.0 Billion While China is Forecast to Grow at 8.4% CAGR

The Lung Disease Therapeutics market in the U.S. is estimated at US$22.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$22.0 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Lung Disease Therapeutics Market – Key Trends & Drivers Summarized

Why Is the Therapeutic Landscape for Lung Diseases Undergoing a Paradigm Shift?

Lung disease therapeutics are experiencing a significant shift in focus and innovation, driven by the growing global burden of respiratory illnesses and the increasing need for more effective, targeted, and sustainable treatment approaches. Chronic and acute lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and interstitial lung disease are becoming more prevalent due to factors such as rising air pollution, smoking, occupational exposures, and aging populations. Historically, lung conditions were managed primarily through bronchodilators, corticosteroids, and antibiotics. However, these treatments often addressed symptoms rather than underlying causes. In recent years, advances in molecular biology, immunology, and pharmacogenomics have led to the development of therapies that specifically target disease mechanisms and cellular pathways. Biologics, such as monoclonal antibodies, and small molecule inhibitors are being designed to control inflammation, halt fibrosis, and improve lung function with greater precision. Inhalation therapies are also being re-engineered to ensure better drug delivery to deep lung tissues, improving treatment efficacy while minimizing systemic side effects. The therapeutic landscape is evolving from generalized symptomatic relief to personalized care plans that integrate patient-specific diagnostics and comorbidity considerations. With respiratory health becoming a global priority, particularly following the COVID-19 pandemic, the demand for advanced lung disease treatments is intensifying across healthcare systems. This paradigm shift reflects a broader commitment to improving long-term respiratory outcomes and reducing the economic and societal impact of chronic lung conditions.

How Are Innovative Therapeutic Approaches Reshaping the Management of Respiratory Disorders?

Innovative therapeutic approaches are reshaping the management of lung diseases by introducing new classes of drugs, novel delivery systems, and regenerative medicine strategies aimed at altering disease progression rather than merely managing symptoms. In the case of asthma and COPD, targeted biologic therapies such as anti-IgE, anti-IL-5, and anti-IL-4 receptor antibodies are transforming outcomes for patients with severe, treatment-resistant forms of these conditions. These biologics block specific inflammatory pathways, reducing exacerbations and improving lung function in ways that traditional inhaled medications cannot achieve alone. In pulmonary fibrosis and interstitial lung diseases, antifibrotic agents like pirfenidone and nintedanib are slowing the decline in lung capacity, providing hope for conditions that were once considered untreatable. The integration of gene therapy and RNA-based treatments is under exploration, particularly for rare genetic lung diseases like cystic fibrosis, offering the potential for long-term correction of the underlying genetic defects. Stem cell therapies are also being investigated for their potential to regenerate damaged lung tissue and restore respiratory function. Additionally, the development of smart inhalers and digital therapeutics is improving patient adherence and enabling real-time monitoring of disease control through connected devices and health platforms. These tools collect usage data and environmental inputs, helping clinicians optimize treatment regimens. These cutting-edge therapies are being tailored to individual patient profiles through biomarker testing and precision medicine approaches, paving the way for more personalized and effective lung disease management that extends far beyond conventional treatment paradigms.

What Are the Emerging Trends in Patient-Centered Lung Disease Treatment and Monitoring?

Patient-centered treatment and monitoring are becoming central to lung disease therapeutics, with a growing emphasis on personalization, convenience, and long-term disease control. As chronic respiratory illnesses often require lifelong management, the healthcare industry is increasingly adopting strategies that enhance the patient experience while ensuring clinical effectiveness. One notable trend is the expansion of home-based care models, supported by portable oxygen concentrators, nebulizers, and telemedicine platforms that allow patients to receive ongoing care without frequent hospital visits. Remote patient monitoring tools, including wearable devices and mobile applications, track key indicators such as oxygen saturation, peak flow rates, and medication adherence, empowering patients and caregivers with actionable insights. Pharmacological advancements are being paired with lifestyle management programs, smoking cessation support, pulmonary rehabilitation, and nutrition counseling to deliver comprehensive care. Treatment plans are increasingly built around patient preferences, genetic makeup, and environmental exposure history to ensure better compliance and outcomes. Multidisciplinary collaboration among pulmonologists, primary care providers, pharmacists, and respiratory therapists is improving care coordination and reducing hospital readmissions. Clinical decision support systems powered by artificial intelligence are helping providers identify the best therapeutic options based on real-time patient data. Furthermore, education campaigns and patient advocacy groups are playing a key role in raising awareness, improving early diagnosis, and advocating for access to newer therapies. These emerging trends reflect a broader healthcare movement toward value-based care, where the goal is not only to manage symptoms but also to enhance quality of life and long-term respiratory well-being for those living with chronic lung disease.

What Are the Main Drivers Fueling the Growth of the Global Lung Disease Therapeutics Market?

The growth in the global lung disease therapeutics market is being driven by a combination of demographic, environmental, technological, and policy-related factors. A key driver is the increasing prevalence of chronic respiratory diseases worldwide, spurred by rising levels of air pollution, tobacco use, sedentary lifestyles, and aging populations, especially in urbanized and industrializing regions. This growing disease burden is prompting healthcare systems and governments to allocate more resources toward respiratory care, including advanced diagnostic tools, expanded screening programs, and wider therapeutic access. The development and approval of new drugs, including biologics and small molecule therapies, are expanding treatment options and meeting the needs of previously underserved patient populations. The momentum in pharmaceutical research, supported by large-scale clinical trials and public-private partnerships, is fostering rapid innovation and faster regulatory approvals. Additionally, the increasing penetration of digital health solutions and remote monitoring tools is enabling more efficient and cost-effective management of lung diseases. Health insurance coverage for advanced therapies is also improving in many countries, encouraging greater adoption and access. Heightened awareness of respiratory health following the global COVID-19 pandemic has further accelerated investments in pulmonary research and infrastructure. Moreover, the growing emphasis on personalized and precision medicine is pushing companies to develop targeted therapies that improve patient outcomes while minimizing side effects. Together, these drivers are creating a dynamic and robust environment for growth, positioning the lung disease therapeutics market as a critical pillar in global healthcare and an area of continued scientific and commercial focus.

SCOPE OF STUDY:

The report analyzes the Lung Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Disease (Asthma Disease, Lung Cancer Disease, Chronic Obstructive Pulmonary Disease); Drug Class (Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents, Mucolytic Drugs); Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Chiesi Farmaceutici S.p.A.
  • Cipla Ltd
  • Gilead Sciences
  • GlaxoSmithKline plc (GSK)
  • Hoffmann-La Roche Ltd (Roche)
  • Ionis Pharmaceuticals Inc.
  • Johnson & Johnson (Janssen)
  • Merck & Co. Inc.
  • Mylan N.V. (part of Viatris)
  • Nektar Therapeutics Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Table of Contents

389 Pages
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Lung Disease Therapeutics – Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Chronic Disease Burden Throws the Spotlight on Long-Term Therapeutic Management for Lung Disorders
Rising Air Pollution Levels Spur Demand for Preventive and Curative Pulmonary Therapies
Breakthrough Biologics & Targeted Therapies Expand the Addressable Market for Complex Lung Diseases
Aging Global Population Strengthens the Business Case for Chronic Obstructive Pulmonary Disease (COPD) Treatments
Digital Health Integration Accelerates Demand for Remote Monitoring and Personalized Respiratory Care Solutions
Surging Cases of Post-COVID Pulmonary Complications Drive Adoption of Advanced Lung Recovery Therapeutics
Innovations in Inhalation Drug Delivery Systems Propel Growth in Patient-Centric Treatment Models
Advancements in Gene & Cell Therapy Open New Frontiers in Refractory Lung Disease Management
Growing Emphasis on Early Diagnosis Sustains Growth Momentum for Companion Diagnostic-Linked Therapies
Real-World Evidence (RWE) and AI-Driven Clinical Insights Bolster Confidence in New Drug Pipelines
Heightened Awareness Campaigns Around Smoking Cessation Generate Demand for Preventive Therapeutic Programs
Shift Toward Value-Based Healthcare Models Elevates the Role of Cost-Effective, Outcome-Driven Lung Treatments
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Lung Disease Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Lung Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Lung Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Asthma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Lung Cancer Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Lung Cancer Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Lung Cancer Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Chronic Obstructive Pulmonary Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 28: World 16-Year Perspective for Corticosteroid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Bronchodilator Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Bronchodilator Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 31: World 16-Year Perspective for Bronchodilator Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Antimicrobial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Antimicrobial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 34: World 16-Year Perspective for Antimicrobial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 37: World 16-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Mucolytic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Mucolytic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 40: World 16-Year Perspective for Mucolytic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 41: USA Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 43: USA 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 46: USA 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 49: USA 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
CANADA
TABLE 50: Canada Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 52: Canada 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 55: Canada 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 58: Canada 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
JAPAN
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 59: Japan Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 61: Japan 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 64: Japan 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 65: Japan Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 67: Japan 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
CHINA
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 68: China Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 70: China 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: China Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 73: China 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 74: China Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: China Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 76: China 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
EUROPE
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 77: Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Lung Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 79: Europe 16-Year Perspective for Lung Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 82: Europe 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 85: Europe 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 88: Europe 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
FRANCE
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 89: France Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 91: France 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: France Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 94: France 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 95: France Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: France Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 97: France 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
GERMANY
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 98: Germany Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 100: Germany 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 103: Germany 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 104: Germany Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Germany Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 106: Germany 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
ITALY
TABLE 107: Italy Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 109: Italy 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 112: Italy 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 113: Italy Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Italy Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 115: Italy 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
UNITED KINGDOM
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 116: UK Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 118: UK 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: UK Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 121: UK 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 122: UK Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: UK Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 124: UK 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
SPAIN
TABLE 125: Spain Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 127: Spain 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 128: Spain Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Spain Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 130: Spain 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 131: Spain Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Spain Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 133: Spain 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
RUSSIA
TABLE 134: Russia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 136: Russia 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 137: Russia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Russia Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 139: Russia 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 140: Russia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Russia Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 142: Russia 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 145: Rest of Europe 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 148: Rest of Europe 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Rest of Europe Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 151: Rest of Europe 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Lung Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 154: Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 157: Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 160: Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Asia-Pacific Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 163: Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
AUSTRALIA
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 164: Australia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 166: Australia 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 167: Australia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Australia Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 169: Australia 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 170: Australia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: Australia Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 172: Australia 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
INDIA
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 173: India Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: India Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 175: India 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 176: India Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: India Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 178: India 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 179: India Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: India Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 181: India 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 182: South Korea Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 184: South Korea 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 185: South Korea Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 187: South Korea 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 188: South Korea Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: South Korea Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 190: South Korea 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Rest of Asia-Pacific Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
LATIN AMERICA
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 200: Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Lung Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 202: Latin America 16-Year Perspective for Lung Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 205: Latin America 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 208: Latin America 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 209: Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Latin America Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 211: Latin America 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 212: Argentina Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 214: Argentina 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 215: Argentina Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 217: Argentina 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 218: Argentina Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Argentina Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 220: Argentina 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
BRAZIL
TABLE 221: Brazil Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 223: Brazil 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 224: Brazil Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 226: Brazil 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 227: Brazil Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Brazil Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 229: Brazil 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
MEXICO
TABLE 230: Mexico Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 232: Mexico 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 233: Mexico Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 235: Mexico 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 236: Mexico Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Mexico Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 238: Mexico 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 241: Rest of Latin America 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 244: Rest of Latin America 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Rest of Latin America Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 247: Rest of Latin America 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
MIDDLE EAST
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 248: Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Lung Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 250: Middle East 16-Year Perspective for Lung Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 253: Middle East 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 256: Middle East 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 257: Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Middle East Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 259: Middle East 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
IRAN
TABLE 260: Iran Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 262: Iran 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 263: Iran Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Iran Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 265: Iran 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 266: Iran Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Iran Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 268: Iran 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
ISRAEL
TABLE 269: Israel Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 271: Israel 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 272: Israel Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Israel Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 274: Israel 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 275: Israel Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Israel Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 277: Israel 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 280: Saudi Arabia 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 283: Saudi Arabia 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: Saudi Arabia Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 286: Saudi Arabia 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 287: UAE Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 289: UAE 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 290: UAE Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: UAE Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 292: UAE 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 293: UAE Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: UAE Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 295: UAE 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 298: Rest of Middle East 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 301: Rest of Middle East 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Rest of Middle East Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 304: Rest of Middle East 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
AFRICA
Lung Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 305: Africa Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Lung Disease Therapeutics by Disease - Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 307: Africa 16-Year Perspective for Lung Disease Therapeutics by Disease - Percentage Breakdown of Value Sales for Asthma Disease, Lung Cancer Disease and Chronic Obstructive Pulmonary Disease for the Years 2014, 2025 & 2030
TABLE 308: Africa Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 309: Africa Historic Review for Lung Disease Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 310: Africa 16-Year Perspective for Lung Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Radiation Therapy and Chemotherapy for the Years 2014, 2025 & 2030
TABLE 311: Africa Recent Past, Current & Future Analysis for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 312: Africa Historic Review for Lung Disease Therapeutics by Drug Class - Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 313: Africa 16-Year Perspective for Lung Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Corticosteroid Drugs, Bronchodilator Drugs, Antimicrobial Drugs, Alkylating Agents and Mucolytic Drugs for the Years 2014, 2025 & 2030
IV. COMPETITION
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.